TERT and cancer: The TERT promoter mutations were found to be the most common point mutations in several types of cancer, including 60–100% of glioblastoma [5, 10, 32, 33], 22–71% of melanoma [4, 15, 34], 29–100% of bladder cancer [3, 35–38], and 29–65% of hepatocellular carcinoma [39–41] cases (Table 2).